 |
| |
| Jul-12-19 | Downgrade |
BofA/Merrill |
Buy → Underperform |
|
|
| May-30-19 | Initiated |
Wolfe Research |
Outperform |
|
|
| Jan-03-19 | Upgrade |
UBS |
Neutral → Buy |
|
|
| Oct-09-18 | Initiated |
UBS |
Neutral |
|
|
| Aug-07-18 | Upgrade |
Morgan Stanley |
Underweight → Equal-Weight |
|
|
| Jul-31-18 | Reiterated |
Canaccord Genuity |
Buy |
$330 → $340 |
|
| Feb-05-18 | Upgrade |
Citigroup |
Neutral → Buy |
|
|
| Jan-31-18 | Upgrade |
First Analysis Sec |
Equal-Weight → Overweight |
$277 |
|
| Jan-05-18 | Initiated |
BTIG Research |
Neutral |
|
|
| Jan-05-18 | Downgrade |
William Blair |
Outperform → Mkt Perform |
|
|
| Jan-02-18 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Oct-25-17 | Upgrade |
Robert W. Baird |
Neutral → Outperform |
$184 → $228 |
|
| Oct-23-17 | Upgrade |
Janney |
Sell → Neutral |
|
|
| Oct-23-17 | Upgrade |
Deutsche Bank |
Hold → Buy |
$195 → $250 |
|
| Sep-26-17 | Resumed |
Goldman |
Neutral |
$200 |
|
| Aug-07-17 | Upgrade |
Canaccord Genuity |
Hold → Buy |
$170 → $215 |
|
| Aug-02-17 | Upgrade |
First Analysis Sec |
Underweight → Equal-Weight |
|
|
| Apr-26-17 | Reiterated |
Cantor Fitzgerald |
Neutral |
$155 → $170 |
|
| Mar-20-17 | Upgrade |
Leerink Partners |
Mkt Perform → Outperform |
|
|
| Feb-01-17 | Reiterated |
UBS |
Buy |
$180 → $185 |
|
|
|
| Jul-22-19 10:31AM | Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for Zacks |
| 10:06AM | What Happens If Pacific Biosciences Isn't Acquired By Illumina? Motley Fool |
| Jul-19-19 12:13PM | Here's Why Pacific Biosciences Is Tumbling Today Motley Fool |
| Jul-18-19 11:26AM | Here's 2 Very Lucrative Trades From My New Trading Venture TheStreet.com |
| 09:30AM | EXEL or ILMN: Which Is the Better Value Stock Right Now? Zacks |
| Jul-16-19 02:00AM | Illumina Expands Genomics Accelerator to Cambridge, UK Business Wire |
| Jul-15-19 05:50PM | Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks |
| 09:31AM | Company News for Jul 15, 2019 Zacks |
| Jul-12-19 05:05PM | What Happened in the Stock Market Today Motley Fool -16.12% |
| 04:29PM | Nasdaq Today: Amazon Prime Day; Facebook Settles With FTC InvestorPlace |
| 04:25PM | S&P 500, Dow, Nasdaq close at record levels again as bulls bank on Fed rate cut MarketWatch |
| 04:18PM | This Genomics Stock Just Lost A Breakout Why Analysts Still Like It Investor's Business Daily |
| 04:16PM | 4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB InvestorPlace |
| 03:46PM | 4 Healthcare Stocks That Are Feeling Sick InvestorPlace |
| 03:32PM | Here's Why NanoString Technologies Stock Soared 104.7% in the First Half of 2019 Motley Fool |
| 03:28PM | Illumina nosedives as company cuts revenue outlook Yahoo Finance Video |
| 12:48PM | Illumina News: Why ILMN Stock Is Plummeting InvestorPlace |
| 11:56AM | Stock Market News: Facebook Faces New Crypto Criticism; Illumina's Revenue Falls Short Motley Fool |
| 11:25AM | Why Illumina Stock Is Tanking Today Motley Fool |
| 10:45AM | BofA Double Downgrades Illumina After Thursday's 'Big Miss' Benzinga |
| 10:13AM | Dow Jones Hits Record Highs To Lead Stock Market Rally; Illumina Plunges Investor's Business Daily |
| 10:01AM | Illumina, One of My Short Stock Candidates, Shows Mediocre Growth TheStreet.com |
| 10:00AM | Illumina's stock tumbles after revenue warning prompts double downgrade at BofA Merrill Lynch MarketWatch |
| 09:04AM | Illumina Stock Is Plummeting but Analysts Still Favor Genome Company Barrons.com |
| 09:01AM | Illumina Stock Plunges While the Dow Is Rising for a Third Day Barrons.com |
| 07:58AM | Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails Investor's Business Daily |
| 07:24AM | The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study Benzinga |
| 06:08AM | Will Illumina, Inc.'s (NASDAQ:ILMN) Earnings Grow Over The Next Year? Simply Wall St. |
| 05:57AM | Illumina Plunges on Lower Second-Quarter Guidance TheStreet.com |
| Jul-11-19 09:39PM | After Hours: Illumina Issues a Warning, Colgate-Palmolive Makes an Acquisition Motley Fool |
| 04:26PM | Illumina stock plunges more than 14% after genetics company lowers guidance MarketWatch |
| 04:05PM | Illumina Reports Preliminary Revenue for Second Quarter of Fiscal Year 2019 Business Wire |
| 12:02PM | California biotech takes 13,000 square feet at UM BioPark American City Business Journals |
| 11:10AM | Illumina (ILMN) Grows on Innovation & International Growth Zacks |
| Jul-10-19 04:23PM | DOJ and SEC charge accountant and friend with insider trading MarketWatch |
| Jul-09-19 05:50PM | Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know Zacks |
| Jul-08-19 10:34AM | Illumina (ILMN) Hits 52-Week High, Can the Run Continue? Zacks |
| Jul-07-19 12:16PM | 5 Great Stocks to Buy in July Motley Fool |
| 07:00AM | Oxford Nanopore opens DNA decoding kit factory Financial Times |
| 05:00AM | As 'Precision Medicine' Starts to Take Off, Here's Who's Poised to Capitalize TheStreet.com |
| Jul-04-19 06:09PM | Why Illumina Stock Jumped 20% in June Motley Fool |
| Jul-03-19 07:17PM | Illumina Inc (ILMN) President and CEO Francis A Desouza Sold $1.1 million of Shares GuruFocus.com |
| 05:45PM | Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know Zacks |
| Jul-02-19 06:18PM | Five Runaway Breakout Stocks to Buy Zacks |
| 03:40PM | Baron Capital Commentary: Early Detection for the Win GuruFocus.com |
| Jul-01-19 02:02PM | Is Now An Opportune Moment To Examine Illumina, Inc. (NASDAQ:ILMN)? Simply Wall St. |
| Jun-28-19 09:00AM | Illumina Files Patent Infringement Suits Related to BGI in Switzerland, Turkey and the US Business Wire |
| Jun-25-19 05:50PM | Illumina (ILMN) Gains As Market Dips: What You Should Know Zacks |
| 05:18PM | Best Growth Stocks for July 2019 Investopedia |
| Jun-24-19 04:23PM | Why These Innovative Biotech ETFs Soaring Zacks |
| Jun-21-19 10:42AM | The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Zacks |
| 10:37AM | The Zacks Analyst Blog Highlights: Middlesex Water, Atlantic Power, NexPoint Residential Trust, Illumina and BioDelivery Sciences International Zacks |
| Jun-20-19 09:18AM | 5 Top Rate-Sensitive Stocks to Buy Amid Fed's Rate Cut Hints Zacks |
| Jun-19-19 06:41PM | 46 and You: Genetic Testing = Giant Growth Market Zacks |
| 09:15AM | They Meet, We Rally Zacks |
| Jun-18-19 05:45PM | Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know Zacks |
| 10:09AM | Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal TheStreet.com |
| Jun-17-19 04:05PM | Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc. Business Wire |
| Jun-14-19 11:02AM | Moving Average Crossover Alert: Illumina Zacks |
| 09:30AM | GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks |
| 09:23AM | Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion Zacks |
| Jun-12-19 05:50PM | Illumina (ILMN) Gains As Market Dips: What You Should Know Zacks |
| 10:03AM | The Zacks Analyst Blog Highlights: American International, Arconic, Hasbro, Illumina and Jefferies Zacks |
| Jun-11-19 07:47AM | 5 Top S&P 500 Stocks to Fly High Despite Market Volatility Zacks |
| 07:17AM | Better Buy: Illumina vs. Guardant Health Motley Fool |
| Jun-10-19 08:19PM | Heres What Hedge Funds Think About Illumina, Inc. (ILMN) Insider Monkey |
| Jun-09-19 12:15PM | 3 Healthcare Stocks I'd Buy Right Now Motley Fool |
| Jun-07-19 04:43PM | Getting technical: Stocks love the 'Fed put'; Tesla still in a down trend traders to sell the rally Yahoo Finance Video +5.31% |
| Jun-06-19 05:45PM | Illumina (ILMN) Gains But Lags Market: What You Should Know Zacks |
| 01:55PM | Top 5 Stocks in the Fight Against Cancer Motley Fool |
| Jun-05-19 09:44AM | The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne Zacks |
| Jun-04-19 03:02PM | Is Illumina, Inc.'s (NASDAQ:ILMN) ROE Of 20% Impressive? Simply Wall St. |
| 02:12PM | 5 Biotech Stocks to Buy Right Now Zacks |
| 09:00AM | Illumina Introduces Expanded Version of VeriSeq NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions Business Wire |
| May-30-19 06:53AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
| May-29-19 04:05PM | Illumina to Webcast Upcoming Investor Conference Presentation Business Wire |
| 09:30AM | GILD or ILMN: Which Is the Better Value Stock Right Now? Zacks |
| May-28-19 11:18AM | Why Illumina (ILMN) Could Be an Impressive Growth Stock Zacks |
| 09:47AM | Illumina, Wix.com, Microsoft, Facebook and Oracle highlighted as Zacks Bull and Bear of the Day Zacks |
| 08:46AM | The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer Zacks |
| 05:43AM | Bull of the Day: Illumina (ILMN) Zacks |
| May-25-19 09:31AM | Illumina (ILMN) Down 2.1% Since Last Earnings Report: Can It Rebound? Zacks |
| May-24-19 09:25AM | 3 Stocks to Win Big in the Fight Against Cancer Zacks |
| May-23-19 09:30AM | Has Illumina (ILMN) Outpaced Other Medical Stocks This Year? Zacks |
| 08:15AM | 3 Cancer Treatment Stocks to Buy Right Now Motley Fool |
| May-21-19 06:11AM | Who's Winning the Race for This $100 Billion Healthcare Market? Motley Fool |
| May-20-19 07:40AM | 3 Top Healthcare Stocks to Buy Right Now Motley Fool |
| May-19-19 12:23PM | 3 Healthcare Stocks I'd Buy Right Now Motley Fool |
| 10:53AM | Top 5 Health Care Stocks of 2018 by Performance Investopedia |
| May-17-19 02:34PM | Final trades: Illumina, Home Depot & Colgate CNBC Videos |
| May-16-19 10:37PM | UK life science companies show signs of health Financial Times |
| May-15-19 09:00AM | Illumina Files Patent Infringement Suit Against BGI in Denmark Business Wire |
| May-14-19 01:50PM | Is Illumina, Inc.'s (NASDAQ:ILMN) CEO Overpaid Relative To Its Peers? Simply Wall St. |
| May-13-19 09:30AM | GILD vs. ILMN: Which Stock Is the Better Value Option? Zacks |
| 08:41AM | Here's Why You Should Invest in Illumina (ILMN) Stock Now Zacks |
| May-08-19 08:45PM | 3 Stocks to Buy and Hold for Decades Motley Fool |
| 02:32PM | Human lifespan could soon pass 100 years thanks to medical tech, says BofA CNBC |
| 01:54PM | Final Trades: Disney, Illumina, Impinj & Gold CNBC Videos |
| 11:00AM | App Store for DNA Fizzles as Health Startup Shifts Strategy Bloomberg |
| 08:03AM | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks |
|
|
|
|
| Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. The company also provides various library preparation and sequencing kits to simplify workflows and accelerate analysis; and genome sequencing, genotyping, and noninvasive prenatal testing, as well as products support services. It serves genomic research centers, academic institutions, government laboratories, and hospitals; and pharmaceutical, biotechnology, and commercial molecular diagnostic laboratories, as well as consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. has a partnership with Lundbeck Foundation GeoGenetics Centre for exploring the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens; and an agreement with HTG Molecular Diagnostics, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. It operates in North America, Europe, Latin America, the Asia-Pacific region, the Middle East, and South Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Ronaghi Mostafa | SVP & CTO | Jul 15 | Option Exercise | 69.34 | 10,000 | 693,400 | 86,776 | Jul 18 11:38 AM | | Ronaghi Mostafa | SVP & CTO | Jul 15 | Sale | 302.04 | 10,000 | 3,020,392 | 76,776 | Jul 18 11:38 AM | | FLATLEY JAY T | Director | Jul 10 | Sale | 376.50 | 3,300 | 1,242,450 | 272,616 | Jul 12 06:19 PM | | deSouza Francis A | President and CEO | Jul 01 | Sale | 369.55 | 3,000 | 1,108,655 | 64,936 | Jul 03 04:50 PM | | Dadswell Charles | SVP & General Counsel | Jul 01 | Sale | 371.29 | 124 | 46,040 | 6,679 | Jul 03 04:47 PM | | FLATLEY JAY T | Director | Jun 26 | Sale | 358.15 | 3,300 | 1,181,895 | 275,916 | Jun 28 04:06 PM | | Ronaghi Mostafa | SVP & CTO | Jun 17 | Option Exercise | 69.34 | 10,000 | 693,400 | 86,776 | Jun 19 07:07 PM | | Ronaghi Mostafa | SVP & CTO | Jun 17 | Sale | 349.28 | 10,000 | 3,492,753 | 76,776 | Jun 19 07:07 PM | | FLATLEY JAY T | Director | Jun 12 | Sale | 334.53 | 3,300 | 1,103,949 | 279,216 | Jun 14 04:00 PM | | OSTADAN OMEAD | SVP Mktg, Prod & Strat Plan | Jun 10 | Sale | 335.03 | 1,260 | 422,138 | 11,945 | Jun 12 04:05 PM | | deSouza Francis A | President and CEO | Jun 03 | Sale | 309.69 | 3,000 | 929,080 | 67,936 | Jun 05 04:34 PM | | Dadswell Charles | SVP & General Counsel | Jun 03 | Sale | 309.70 | 1,220 | 377,838 | 6,866 | Jun 05 04:27 PM | | FLATLEY JAY T | Director | May 22 | Sale | 304.44 | 3,300 | 1,004,652 | 282,516 | May 24 05:22 PM | | Ronaghi Mostafa | SVP & CTO | May 15 | Option Exercise | 69.34 | 10,000 | 693,400 | 87,414 | May 16 08:34 PM | | Ronaghi Mostafa | SVP & CTO | May 15 | Sale | 305.49 | 10,000 | 3,054,876 | 77,414 | May 16 08:34 PM | | ARNOLD FRANCES | Director | May 13 | Sale | 307.95 | 1,503 | 462,849 | 10,159 | May 15 04:44 PM | | OSTADAN OMEAD | SVP Mktg, Prod & Strat Plan | May 10 | Sale | 315.32 | 1,260 | 397,303 | 13,205 | May 13 07:42 PM | | FLATLEY JAY T | Director | May 08 | Sale | 318.59 | 3,300 | 1,051,347 | 285,816 | May 10 05:50 PM | | EPSTEIN ROBERT S | Director | May 01 | Option Exercise | 51.17 | 5,000 | 255,850 | 8,256 | May 03 05:18 PM | | EPSTEIN ROBERT S | Director | May 01 | Sale | 310.44 | 5,000 | 1,552,178 | 3,256 | May 03 05:18 PM | | deSouza Francis A | President and CEO | May 01 | Sale | 310.01 | 3,000 | 930,029 | 70,936 | May 03 05:12 PM | | Dadswell Charles | SVP & General Counsel | May 01 | Sale | 311.77 | 124 | 38,659 | 8,086 | May 03 05:07 PM | | FLATLEY JAY T | Director | Apr 24 | Sale | 321.96 | 3,300 | 1,062,468 | 289,116 | Apr 26 05:29 PM | | FLATLEY JAY T | Director | Apr 10 | Sale | 317.01 | 3,300 | 1,046,133 | 331,668 | Apr 12 04:33 PM | | EPSTEIN ROBERT S | Director | Apr 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 4,256 | Apr 03 05:28 PM | | deSouza Francis A | President and CEO | Apr 01 | Sale | 315.93 | 3,000 | 947,788 | 73,746 | Apr 03 05:25 PM | | Dadswell Charles | SVP & General Counsel | Apr 01 | Sale | 314.45 | 124 | 38,992 | 8,210 | Apr 03 05:22 PM | | EPSTEIN ROBERT S | Director | Apr 01 | Sale | 314.45 | 1,000 | 314,450 | 3,256 | Apr 03 05:28 PM | | FLATLEY JAY T | Director | Mar 27 | Sale | 306.93 | 3,300 | 1,012,869 | 334,968 | Mar 29 04:01 PM | | FLATLEY JAY T | Director | Mar 13 | Sale | 306.50 | 3,300 | 1,011,450 | 338,268 | Mar 29 04:01 PM | | EPSTEIN ROBERT S | Director | Mar 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 4,256 | Mar 05 04:57 PM | | deSouza Francis A | President and CEO | Mar 01 | Sale | 316.51 | 3,000 | 949,518 | 76,746 | Mar 05 04:58 PM | | Dadswell Charles | SVP & General Counsel | Mar 01 | Sale | 313.93 | 1,220 | 382,995 | 8,334 | Mar 05 04:56 PM | | EPSTEIN ROBERT S | Director | Mar 01 | Sale | 313.93 | 1,000 | 313,930 | 3,256 | Mar 05 04:57 PM | | FLATLEY JAY T | Director | Feb 27 | Sale | 300.00 | 3,300 | 990,000 | 341,568 | Mar 01 05:23 PM | | Hoyt Aimee L | SVP, Chief People Officer | Feb 26 | Sale | 304.63 | 298 | 90,780 | 2,297 | Feb 28 05:30 PM | | OSTADAN OMEAD | SVP Mktg, Prod & Strat Plan | Feb 15 | Sale | 294.62 | 1,260 | 371,216 | 29,420 | Feb 19 07:02 PM | | FLATLEY JAY T | Director | Feb 13 | Sale | 293.66 | 3,300 | 969,078 | 344,868 | Feb 14 04:21 PM | | Van Oene Mark | SVP Chief Commercial Officer | Feb 12 | Option Exercise | 0.00 | 5,639 | 0 | 15,419 | Feb 14 04:36 PM | | Ronaghi Mostafa | SVP & CTO | Feb 12 | Option Exercise | 0.00 | 9,782 | 0 | 79,217 | Feb 14 04:34 PM | | RAGUSA ROBERT P | SVP, Global Quality & Ops | Feb 12 | Option Exercise | 0.00 | 4,540 | 0 | 15,316 | Feb 14 04:32 PM | | OSTADAN OMEAD | SVP Mktg, Prod & Strat Plan | Feb 12 | Option Exercise | 0.00 | 9,492 | 0 | 33,875 | Feb 14 04:23 PM | | FLATLEY JAY T | Director | Feb 12 | Option Exercise | 0.00 | 28,888 | 0 | 358,929 | Feb 14 04:21 PM | | deSouza Francis A | President and CEO | Feb 12 | Option Exercise | 0.00 | 24,621 | 0 | 82,910 | Feb 14 04:17 PM | | Dadswell Charles | SVP & General Counsel | Feb 12 | Option Exercise | 0.00 | 4,127 | 0 | 11,064 | Feb 14 04:15 PM | | EPSTEIN ROBERT S | Director | Feb 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 4,256 | Feb 05 04:45 PM | | Dadswell Charles | SVP & General Counsel | Feb 01 | Sale | 280.11 | 124 | 34,734 | 6,879 | Feb 05 04:44 PM | | deSouza Francis A | President and CEO | Feb 01 | Sale | 282.95 | 3,000 | 848,854 | 64,104 | Feb 05 04:46 PM | | EPSTEIN ROBERT S | Director | Feb 01 | Sale | 280.11 | 1,000 | 280,110 | 3,256 | Feb 05 04:45 PM | | FLATLEY JAY T | Director | Jan 23 | Sale | 303.53 | 3,300 | 1,001,649 | 329,979 | Jan 25 04:27 PM | | FLATLEY JAY T | Director | Jan 09 | Sale | 296.20 | 3,300 | 977,460 | 333,279 | Jan 11 04:35 PM | | EASTHAM KARIN | Director | Jan 02 | Option Exercise | 71.09 | 4,000 | 284,360 | 15,838 | Jan 04 05:03 PM | | EPSTEIN ROBERT S | Director | Jan 02 | Option Exercise | 51.17 | 1,000 | 51,170 | 4,256 | Jan 04 05:05 PM | | EPSTEIN ROBERT S | Director | Jan 02 | Sale | 294.71 | 1,000 | 294,710 | 3,256 | Jan 04 05:05 PM | | deSouza Francis A | President and CEO | Jan 02 | Sale | 293.33 | 3,000 | 879,994 | 67,104 | Jan 04 05:04 PM | | EASTHAM KARIN | Director | Jan 02 | Sale | 294.08 | 5,000 | 1,470,381 | 10,838 | Jan 04 05:03 PM | | Dadswell Charles | Sr VP & General Counsel | Jan 02 | Sale | 294.71 | 124 | 36,544 | 7,003 | Jan 04 05:01 PM | | FLATLEY JAY T | Director | Dec 26 | Sale | 273.87 | 3,300 | 903,771 | 336,579 | Dec 28 05:36 PM | | FLATLEY JAY T | Director | Dec 12 | Sale | 334.13 | 3,300 | 1,102,629 | 371,559 | Dec 13 07:26 PM | | OSTADAN OMEAD | EVP Ops, Products, Strategy | Dec 10 | Sale | 321.50 | 644 | 207,046 | 21,613 | Dec 12 01:59 PM | | Stapley Marc | EVP Strategy & Corp Developmt | Dec 06 | Sale | 329.69 | 1,000 | 329,695 | 6,957 | Dec 07 05:17 PM | | EPSTEIN ROBERT S | Director | Dec 03 | Option Exercise | 51.17 | 1,000 | 51,170 | 6,101 | Dec 04 09:03 PM | | EPSTEIN ROBERT S | Director | Dec 03 | Sale | 343.57 | 1,345 | 462,102 | 4,756 | Dec 04 09:03 PM | | Dadswell Charles | Sr VP & General Counsel | Dec 03 | Sale | 343.57 | 566 | 194,461 | 5,606 | Dec 04 09:01 PM | | deSouza Francis A | President and CEO | Dec 03 | Sale | 345.90 | 3,000 | 1,037,688 | 63,643 | Dec 04 09:02 PM | | FLATLEY JAY T | Director | Nov 28 | Sale | 321.80 | 3,300 | 1,061,940 | 373,410 | Nov 30 04:24 PM | | OSTADAN OMEAD | EVP Ops, Products, Strategy | Nov 23 | Sale | 306.74 | 644 | 197,541 | 22,257 | Nov 27 04:39 PM | | FLATLEY JAY T | Director | Nov 14 | Sale | 312.50 | 3,300 | 1,031,250 | 376,710 | Nov 16 04:09 PM | | Ronaghi Mostafa | Sr VP & CTO | Nov 12 | Option Exercise | 37.04 | 10,000 | 370,400 | 79,612 | Nov 14 05:44 PM | | Ronaghi Mostafa | Sr VP & CTO | Nov 12 | Sale | 314.63 | 10,000 | 3,146,337 | 69,612 | Nov 14 05:44 PM | | Stapley Marc | EVP Strategy & Corp Developmt | Nov 07 | Sale | 336.68 | 1,000 | 336,680 | 6,957 | Nov 09 04:23 PM | | Van Oene Mark | SVP Chief Commercial Officer | Nov 05 | Option Exercise | 29.44 | 6,000 | 176,640 | 17,126 | Nov 07 05:05 PM | | Van Oene Mark | SVP Chief Commercial Officer | Nov 05 | Sale | 326.11 | 6,835 | 2,228,950 | 10,291 | Nov 07 05:05 PM | | EPSTEIN ROBERT S | Director | Nov 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 6,447 | Nov 02 05:01 PM | | EPSTEIN ROBERT S | Director | Nov 01 | Sale | 311.86 | 1,346 | 419,764 | 5,101 | Nov 02 05:01 PM | | deSouza Francis A | President and CEO | Nov 01 | Sale | 310.85 | 2,100 | 652,788 | 70,235 | Nov 02 05:03 PM | | FLATLEY JAY T | Director | Oct 24 | Sale | 310.58 | 3,300 | 1,024,914 | 382,304 | Oct 26 04:35 PM | | Ronaghi Mostafa | Sr VP & CTO | Oct 10 | Option Exercise | 37.04 | 10,000 | 370,400 | 80,805 | Oct 12 04:37 PM | | Ronaghi Mostafa | Sr VP & CTO | Oct 10 | Sale | 311.84 | 10,000 | 3,118,424 | 70,805 | Oct 12 04:37 PM | | FLATLEY JAY T | Director | Oct 10 | Sale | 321.58 | 3,300 | 1,061,214 | 385,604 | Oct 12 04:35 PM | | EPSTEIN ROBERT S | Director | Oct 01 | Option Exercise | 51.17 | 1,000 | 51,170 | 6,793 | Oct 03 04:17 PM | | deSouza Francis A | President and CEO | Oct 01 | Sale | 369.61 | 2,100 | 776,183 | 72,335 | Oct 03 04:20 PM | | EPSTEIN ROBERT S | Director | Oct 01 | Sale | 369.15 | 1,346 | 496,876 | 5,447 | Oct 03 04:17 PM | | FLATLEY JAY T | Director | Sep 26 | Sale | 360.81 | 3,300 | 1,190,673 | 388,904 | Sep 28 05:29 PM | | FLATLEY JAY T | Director | Sep 12 | Sale | 351.66 | 3,300 | 1,160,478 | 392,204 | Sep 14 09:25 PM | | Ronaghi Mostafa | Sr VP & CTO | Sep 10 | Option Exercise | 37.04 | 10,000 | 370,400 | 80,805 | Sep 11 05:49 PM | | Ronaghi Mostafa | Sr VP & CTO | Sep 10 | Sale | 347.07 | 10,000 | 3,470,709 | 70,805 | Sep 11 05:49 PM | | EPSTEIN ROBERT S | Director | Sep 07 | Option Exercise | 51.17 | 1,000 | 51,170 | 7,139 | Sep 11 05:45 PM | | EPSTEIN ROBERT S | Director | Sep 07 | Sale | 345.14 | 1,346 | 464,558 | 5,793 | Sep 11 05:45 PM | | Stapley Marc | EVP Strategy & Corp Developmt | Sep 04 | Sale | 352.05 | 1,000 | 352,054 | 8,516 | Sep 06 08:22 PM | | deSouza Francis A | President and CEO | Sep 04 | Sale | 353.66 | 2,100 | 742,686 | 74,435 | Sep 06 06:26 PM | | Van Oene Mark | SVP Chief Commercial Officer | Sep 04 | Sale | 354.18 | 1,091 | 386,410 | 11,126 | Sep 06 06:09 PM | | Ronaghi Mostafa | Sr VP & CTO | Aug 10 | Option Exercise | 37.04 | 10,000 | 370,400 | 80,805 | Aug 14 04:07 PM | | Ronaghi Mostafa | Sr VP & CTO | Aug 10 | Sale | 331.39 | 10,000 | 3,313,861 | 70,805 | Aug 14 04:07 PM | | OSTADAN OMEAD | EVP Ops, Products, Strategy | Aug 02 | Sale | 320.70 | 1,334 | 427,814 | 24,484 | Aug 06 08:11 PM | | Stapley Marc | EVP Strategy & Corp Developmt | Aug 02 | Sale | 324.80 | 1,000 | 324,798 | 7,516 | Aug 06 08:10 PM | | deSouza Francis A | President and CEO | Aug 01 | Sale | 327.41 | 2,100 | 687,555 | 76,535 | Aug 03 03:03 PM | | EPSTEIN ROBERT S | Director | Jul 23 | Sale | 311.15 | 500 | 155,575 | 6,139 | Jul 24 07:21 PM |
|
|
|
|
|
|
